Putnam’s Centers of Excellence allow us to dig deep, challenge convention, and take you further with strategies underpinned by technical expertise in cutting-edge topics.
We provide world-class thought partnership and solutions that enhance the business impact of medical and scientific affairs.
A strategic thought partner for your AI journey
Mobile navigation menu modal
Explore our latest insights and perspectives in these life science resources, news articles, and events.
Putnam predicts the 15 drugs likely to be selected for the second round of Medicare Price Negotiations.
The Inflation Reduction Act (IRA) is likely to prompt a range of second-order effects on the pharmaceutical industry...
Putnam, leading scientific and strategic consulting partner, is thrilled to announce Scott Briggs and Thomas Marder have been promoted to Partner...
This paper outlines predictions regarding drugs likely to be impacted by Medicare Price Negotiation in 2026 and implications in subsequent years.
A rapidly shifting healthcare landscape and a wave of cost-containment initiatives destined to put further pressure on the pricing of pharmaceuticals.
Scott Briggs, Principal, joined a live panel of industry experts to discuss the Inflation Reduction Act on March 30th.
Alex Busch, Ph.D., Partner and Scott Briggs, Principal were featured in BioCentury on the Inflation Reduction Act.
Putnam is developing tools and insights to help manufacturers assess and realize opportunities and mitigate risks from Inflation Reduction Act.
Looking to get in touch with an expert or team member?
Tell us how we can help.
